Amonafide

Amonafide

Systematic (IUPAC) name
5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
Identifiers
CAS Number	69408-81-7
ATC code	None
PubChem	CID 50515
ChemSpider	45804
UNII	1Q8D39N37L
KEGG	D10090
ChEMBL	CHEMBL428676
Chemical data
Formula	C16H17N3O3
Molar mass	283.325 g/mol
SMILES O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
InChI InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 Key:UPALIKSFLSVKIS-UHFFFAOYSA-N
(verify)

Amonafide (originally AS1413) (INN, trade name Quinamed) is a drug that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and DNA intercalators.

It is being developed as an anti-cancer therapy by Antisoma.^[1]

As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).^[2]

References

1. http://www.genengnews.com/news/bnitem.aspx?name=78979622
2. http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"

External links

• Amonafide entry in the public domain NCI Dictionary of Cancer Terms
• Clinical trials of amonafide at ClinicalTrials.gov

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".